Research Paper Volume 15, Issue 16 pp 7933—7955
A novel hepatocellular carcinoma-specific mTORC1-related signature for anticipating prognosis and immunotherapy
Figure 2. Development and validation of an HCC-specific mTORC1 signaling-related signature. (A) Kaplan–Meier plots indicate that the OS of patients in the group with high risk was substantially longer compared to those in the group with low risk in the TCGA-LIHC and ICGC-LIRI-JP cohorts. (B) The differences in the mTORC1-related score across groups with high and low risk in the TCGA-LIHC and ICGC-LIRI-JP cohorts. (C) ROC analysis of one-, three- and five-year OS signifying the excellent prognostic significance of mTORC1 score in the TCGA-LIHC cohorts. (D) ROC analysis of one-, and three-year OS signifying the excellent prognostic significance of mTORC1 score in the ICGC-LIRI-JP cohorts. (E) Variations across the groups with high and low risk in terms of various clinicopathological features.